• Email Alerts
  • Careers
  • Contact Us

SCYNEXIS, Inc.

  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
    • Careers
    • Contact
  • Product
    • ibrexafungerp
    • Patent
  • Pipeline
    • Ibrexafungerp Development Pipeline
    • Clinical Trials
    • Vulvovaginal Candidiasis
    • Refractory Invasive Fungal Infections
    • Invasive Candidiasis
    • Invasive Aspergillosis
  • Science
    • SCYNEXIS Research Platform
    • Publications and Presentations
    • Expanded Access
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Data

SCYNEXIS, Inc.

You are now leaving the SCYNEXIS Corporate Website.

I understand Cancel

Posters and Presentations

Science

Science

  • SCYNEXIS Research Platform
  • Publications and Presentations
  • Expanded Access
  • Publications and Presentations

  • Posters and Presentations
Clear Search
Effect of SCY-078 on the Pharmacokinetics of CYP2C8 substrate (Rosiglitazone) - Results from a Phase 1 Clinical Trial

Effect of SCY-078 on the Pharmacokinetics of CYP2C8 substrate (Rosiglitazone) - Results from a Phase 1 Clinical Trial

D. Angulo, G. Atiee, C. Corr, M. Willett, G. Murphy, S. Wring
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

Effect of SCY-078 on the Pharmacokinetics of Tacrolimus: Results from a Phase 1 Clinical Drug-Drug Interaction Trial

Effect of SCY-078 on the Pharmacokinetics of Tacrolimus: Results from a Phase 1 Clinical Drug-Drug Interaction Trial

D. Angulo, G. Atiee, C. Corr, M. Willett, G. Murphy, S. Wring
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

Activity of SCY-078 against <em>Candida spp</em>. obtained by EUCAST and CLSI procedures

Activity of SCY-078 against Candida spp. obtained by EUCAST and CLSI procedures

L. Marcos-Zambrano, M. Gómez-Perosanz, P. Escribano, E. Bouza Santiago, J.Guinea
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

The Novel Oral Glucan Synthase Inhibitor SCY-078 Shows <em>In Vitro</em> Activity Against <em>Candida spp</em>. Bioflms

The Novel Oral Glucan Synthase Inhibitor SCY-078 Shows In Vitro Activity Against Candida spp. Bioflms

J. Guinea, L. Marcos-Zambrano, M. Gomez-Perosanz, P. Escribano, E. Bouza Santiago
27th European Congress of Clinical Microbiology and Infectious Diseases
April 2017

SCY-078 Displays Potent <em>In Vitro</em> Activity Against <em>Candida glabrata</em> Isolates with Mutations in <em>fks</em> Gene

SCY-078 Displays Potent In Vitro Activity Against Candida glabrata Isolates with Mutations in fks Gene

K. Borroto-Esoda, D. Angulo, M. Castanheira, M. Pfaller, S. Wring
13th American Society for Microbiology (ASM) Conference on Candida and Candidiasis
April 2016

SCY-078 Displays Significant <em>In Vitro</em> Activity Against Multi Drug Resistant (MDR) <em>Candida albicans</em> and <em>Candida glabrata</em> Isolates

SCY-078 Displays Significant In Vitro Activity Against Multi Drug Resistant (MDR) Candida albicans and Candida glabrata Isolates

K. Borroto-Esoda, D. Angulo, S. Moser, J. Whiddon, P. Pappas, S. Wring
13th American Society for Microbiology (ASM) Conference on Candida and Candidiasis
April 2016

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5

1 Evertrust Plaza, Jersey City, NJ 07302
(201) 884-5485
View Google Map

© 2022 SCYNEXIS, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Contact Us